Sun Pharma launches polistirex technology based on Chericof 12



Sun Pharmaceutical Industries today announced the launch of a new formulation for the management of cough – Chericof 12 (dextromethorphan hydrobromide 30 mg and chlorpheniramine maleate 4 mg) in India.

All cough syrups usually provide relief for 6-8 hours, so a patient should take it three to four times a day. Frequent dosing often leads to inconvenience for the patient and non-compliance with the regimen, which can compromise the effectiveness of the drug.

Chericof 12, India’s first prescription cough syrup that provides up to 12 hour relief, is made using polistirex technology for sustained release of the drug.

Polistirex technology involves the complexation of two drugs, dextromethorphan hydrobromide and chlorpheniramine maleate with resins. Complexation of drugs with polistirex not only provides sustained release, but also masks the bitter taste, making it more palatable.

The formulation is approved for patients in the age group six years and older.

Kirti Ganorkar, CEO of Sun Pharma in India, said: The Polistirex technology used in Chericof 12 helps improve patient compliance and avoids the need for frequent dosing.

Sun Pharmaceutical Industries is the world’s fourth largest generic specialty pharmaceutical company and India’s largest pharmaceutical company.

The company reported a consolidated net profit of Rs 1,444.17 crore in the first quarter of fiscal 22, compared with a net loss of Rs 1,655.60 crore in the first quarter of fiscal 21. Net sales in the quarter were increased 29.2% year on year to Rs 9,669.43 crore.

The script lost 0.34% to currently trade at Rs 760.35 on BSE.

Powered by Capital Market – Live News

(This story was not edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear reader,

Business Standard has always strived to provide up-to-date information and commentary on developments that matter to you and have broader political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these difficult times resulting from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative views and cutting-edge commentary on relevant current issues.
However, we have a demand.

As we fight the economic impact of the pandemic, we need your support even more so that we can continue to provide you with more quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of providing you with even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital editor



Leave A Reply